274. Osteogenesis Imperfecta
78 clinical trials,   87 drugs   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways

Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003228-22-GB
(EUCTR)
14/12/201619/10/2016Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acidTreatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study Osteogenesis imperfecta
MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Trade Name: Teriparatide
Product Name: Teriparatide
Trade Name: Zoledronic acid
Product Name: Zoledronic acid
Trade Name: Alendronic acid
Product Name: Alendronic acid
Trade Name: Risedronate sodium
Product Name: Risedronate sodium
Trade Name: Ibandronic acid
Product Name: Ibandronic acid
Trade Name: Ibandronic acid
Product Name: Ibandronic acid
Trade Name: Disodium Pamidronate 15mg (15mg strength)
Product Name: Disodium Pamidronate 15mg (15mg strength)
Trade Name: Prolia
Product Name: Prolia
Trade Name: Bonefos
Product Name: Bonefos
University of EdinburghNHS LothianAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
380Phase 4Ireland;United Kingdom
2NCT03735537
(ClinicalTrials.gov)
November 1, 20169/8/2018Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic AcidTreatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic AcidOsteogenesis ImperfectaDrug: Teriparatide Pen Injector;Drug: Zoledronic AcidUniversity of EdinburghNHS LothianRecruiting18 YearsN/AAll380Phase 4Ireland;United Kingdom
3NCT01679080
(ClinicalTrials.gov)
November 201216/8/2012The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis ImperfectaThe Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis ImperfectaOsteogenesis ImperfectaDrug: Zoledronic acid;Drug: Teriparatide;Other: No active treatmentUniversity of AarhusNULLActive, not recruiting22 Years70 YearsAll80Phase 2Denmark
4NCT00131469
(ClinicalTrials.gov)
June 200516/8/2005Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis ImperfectaA Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI)Osteogenesis ImperfectaDrug: Teriparatide (FORTEO);Drug: PlacebosOregon Health and Science UniversityEli Lilly and Company;Osteogenesis Imperfecta Foundation;National Institutes of Health (NIH);National Center for Research Resources (NCRR)Completed18 Years85 YearsAll79Phase 4United States